126 related articles for article (PubMed ID: 25153418)
1. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome.
Qian J; Chen XX; Qian W; Yang J; Wen XM; Ma JC; Deng ZQ; Qian Z; Zhang YY; Lin J
Clin Chem Lab Med; 2014 Dec; 52(12):1859-65. PubMed ID: 25153418
[TBL] [Abstract][Full Text] [Related]
2. Methylation of CTNNA1 promoter: frequent but not an adverse prognostic factor in acute myeloid leukemia.
Chen XX; Lin J; Qian J; Qian W; Yang J; Ma JC; Deng ZQ; An C; Tang CY; Qian Z; Liu Q
Leuk Res; 2014 May; 38(5):613-8. PubMed ID: 24685333
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome.
Lin J; Wang YL; Qian J; Yao DM; Zhu ZH; Qian Z; Xu WR
Leuk Res; 2010 Aug; 34(8):991-4. PubMed ID: 20116099
[TBL] [Abstract][Full Text] [Related]
4. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
Ye Y; McDevitt MA; Guo M; Zhang W; Galm O; Gore SD; Karp JE; Maciejewski JP; Kowalski J; Tsai HL; Gondek LP; Tsai HC; Wang X; Hooker C; Smith BD; Carraway HE; Herman JG
Cancer Res; 2009 Nov; 69(21):8482-90. PubMed ID: 19826047
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of aberrant SOCS-1 gene promoter methylation in myelodysplastic syndromes patients.
Chaubey R; Sazawal S; Mahapatra M; Chhikara S; Saxena R
Int J Lab Hematol; 2015 Apr; 37(2):265-71. PubMed ID: 25123164
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
7. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome.
Qian J; Yao DM; Lin J; Wang YL; Han LX; Xu WR; Wu CY
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):74-81. PubMed ID: 19196380
[TBL] [Abstract][Full Text] [Related]
8. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX
Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
[TBL] [Abstract][Full Text] [Related]
10. CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
Li M; Gao L; Li Z; Sun J; Zhang H; Duan H; Ma Y; Wang C
Oncotarget; 2016 May; 7(21):31454-65. PubMed ID: 27129146
[TBL] [Abstract][Full Text] [Related]
11. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
[TBL] [Abstract][Full Text] [Related]
12. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P
Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268
[TBL] [Abstract][Full Text] [Related]
14. Abnormal methylation of the sex-determining region Y-box 17 (SOX17) promoter predicts poor prognosis in myelodysplastic syndrome.
Fan R; Zhao XL; Wang H; He HY; Peng ZP; Yang B; Han T; Wang W; Wang XQ; Lin GW
Clin Lab; 2014; 60(9):1465-74. PubMed ID: 25291942
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Yao DM; Ma JC; Wen XM; Guo H; Lin J; Qian J
Clin Chem Lab Med; 2016 May; 54(5):865-71. PubMed ID: 26485746
[TBL] [Abstract][Full Text] [Related]
16. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
17. [Methylation status of ZO-1 gene in patients with myelodysplastic syndrome].
Kang HY; Wang C; Dou LP; Qing Y; Han XP; Sun JF; Liu CH; Lu XC; Liu Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):70-3. PubMed ID: 18315903
[TBL] [Abstract][Full Text] [Related]
18. The lower risk MDS patient at risk of rapid progression.
Mittelman M; Oster HS; Hoffman M; Neumann D
Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
[TBL] [Abstract][Full Text] [Related]
19. [Significance of methylation status of zo-1 gene in differential diagnosis for myelodysplastic syndrome].
Kang HY; Wang XR; Wang LL; Wang C; Cen J; Gao L; Liu Y; Li YH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):76-80. PubMed ID: 21362226
[TBL] [Abstract][Full Text] [Related]
20. [Study of aberrant p73 promoter methylation in patients with myelodysplastic syndrome].
Zhao YS; Yang R; Gu SC; Guo J; Zhang X; Wu LY; Li X; Chang CK
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):847-51. PubMed ID: 23384909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
